Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects

Takeshi Kadokura,Masako Saito,Atsushi Utsuno,Kenichi Kazuta,Satoshi Yoshida,Shigenori Kawasaki,Itsuro Nagase,Shigeru Kageyama

Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects

2011

Takeshi Kadokura
Masako Saito
Atsushi Utsuno
Kenichi Kazuta
Satoshi Yoshida
Shigenori Kawasaki
Itsuro Nagase
Shigeru Kageyama

Background This phase 1, randomized, placebo-controlled, dose-escalation study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ipragliflozin (ASP1941) in healthy Japanese subjects.

Keywords:

Hypoglycemia
Ipragliflozin
Pharmacodynamics
Type 2 Diabetes Mellitus
Urinary system
Medicine
Diabetes mellitus
Endocrinology
Internal medicine
Tolerability
Pharmacokinetics
Excretion

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations